Kent M Adler, MD
Medical Oncology · Burlingame
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 16
- 5 carriers
- Offices
- 2
Offices
2 locations · UCSF Medical Group Business Services · 1,533 clinicians in this group
Looking this up.
Hospitals listed: Mills-Peninsula Medical Center · Sequoia Hospital · Stanford Health Care · UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
16 plans · 5 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Adler’s office at (650) 341-9131 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
16 of 16 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence G60386 · Current
Licensed to practise in California · since 1987 · expires 2027-01-31 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
- Sequoia HospitalRedwood City, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 104.12 (51.8 to 156.44) · 56 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Sequoia Hospital
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 4 the same, 0 worse of 5 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 104.12 (51.8 to 156.44) · 56 cases | Better | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.95 (0 to 1.98) · 472 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.91 (0.58 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.8 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.1 · 258 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.5 · 171 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 81 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,231 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.23 (0.01 to 0.44) · 3,018 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.44) · 3,164 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.59 (0.47 to 4.71) · 1,402 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.47 (0.04 to 2.9) · 926 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.68 (0.21 to 3.16) · 1,310 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.54 (4.42 to 14.67) · 978 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.98 (1.61 to 8.36) · 924 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.69 (0.19 to 3.19) · 192 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.57 (0 to 1.43) · 2,501 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.5 · 332 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.702 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.853 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 67 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 295 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -27.1 · 76 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -22.3 · 304 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -4.6 · 178 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.3 · 180 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 305 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 41 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 29 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.1 (9.7 to 17.7) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 713 cases | No different | Jan 2024 – Dec 2024 |
What patients said (631 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 82% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 81% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 77% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 91% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$3,188,653
Medicare paid this office $3,188,653 for 257 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, pembrolizumab, 1 mg | 15 | $1,234,670 | None |
| Injection, denosumab, 1 mg | 14 | $194,308 | None |
| Administration of chemotherapy into vein, 1 hour or less | 54 | $67,220 | $136 |
| Long return visit (40+ min) | 123 | $48,964 | $165 |
| Return visit (30+ min) | 135 | $25,764 | $113 |
See all 31 services
| Injection, pembrolizumab, 1 mg | 15 | $1,234,670 | None |
| Injection, denosumab, 1 mg | 14 | $194,308 | None |
| Administration of chemotherapy into vein, 1 hour or less | 54 | $67,220 | $136 |
| Long return visit (40+ min) | 123 | $48,964 | $165 |
| Return visit (30+ min) | 135 | $25,764 | $113 |
| Injection, pemetrexed, not otherwise specified, 10 mg | 11 | $19,032 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 30 | $12,080 | $68 |
| Injection, aprepitant, 1 mg | 16 | $10,850 | None |
| Injection of additional new drug or substance into vein | 37 | $8,828 | $16 |
| New patient visit (60+ min) | 40 | $7,794 | $195 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 162 | $6,085 | $15 |
| Collection of blood sample from implanted device | 27 | $5,093 | $30 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 78 | $5,042 | $29 |
| Administration of additional new drug or substance into vein using push technique | 12 | $4,628 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $4,507 | $105 |
| Short return visit (20+ min) | 45 | $4,137 | $78 |
| Administration of chemotherapy into vein, each additional hour | 17 | $3,172 | $29 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 32 | $3,139 | $70 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $2,916 | $153 |
| Injection of drug or substance under skin or into muscle | 34 | $2,198 | $13 |
| Infusion, normal saline solution , 1000 cc | 60 | $1,984 | None |
| Injection, carboplatin, 50 mg | 20 | $1,639 | None |
| Injection, paclitaxel, 1 mg | 12 | $1,201 | None |
| Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th | 12 | $729 | $27 |
| Infusion into a vein for hydration, each additional hour | 14 | $506 | $13 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 11 | $477 | $43 |
| Injection, palonosetron hcl, 25 mcg | 11 | $254 | None |
| 5% dextrose/water (500 ml = 1 unit) | 24 | $203 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 30 | $101 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 17 | $60 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 11 | $44 | None |
Who their Medicare patients are
257 Original Medicare patients in 2024. Average age 78 · Women 61% · Also on Medicaid 5% · Health risk score 1.97. At or below the middle of the specialty; the typical medical oncology clinician is at 2.11.
Conditions among them: High blood pressure 75% · Cancer 74% · Coronary heart disease 33% · Chronic kidney disease 27% · Atrial fibrillation 27% · Diabetes 26% · COPD 22% · Heart failure 17% · Depression 14% · Stroke 9% · Dementia 7%.
The office billed $25,745,604, Medicare allowed $4,010,481 and paid $3,188,653; for 137,909 services of 93 kinds; $2,960,259 of it was for drugs given in the office and $228,395 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 257 | 137,909 | 78 | 1.97 | $25,745,604 | $3,188,653 |
| 2023 | 295 | 101,574 | 77 | 1.88 | $22,770,843 | $2,969,503 |
| 2022 | 292 | 88,454 | 77 | 1.85 | $18,912,685 | $2,703,044 |
| 2021 | 245 | 52,656 | 78 | 1.91 | $11,632,899 | $1,723,584 |
| 2020 | 271 | 53,474 | 77 | 2.27 | $8,058,693 | $1,210,494 |
| 2019 | 369 | 61,248 | 77 | 2.31 | $5,038,745 | $1,455,682 |
| 2018 | 383 | 73,880 | 77 | 2.15 | $5,458,286 | $1,474,269 |
| 2017 | 360 | 48,880 | 77 | 2.06 | $4,148,958 | $1,440,673 |
| 2016 | 415 | 63,644 | 76 | 2.09 | $4,068,196 | $1,294,878 |
| 2015 | 405 | 46,502 | 77 | 1.95 | $2,470,325 | $838,883 |
| 2014 | 349 | 41,247 | 76 | 2.06 | $2,126,102 | $753,547 |
| 2013 | 336 | 29,124 | 76 | 1.87 | $1,702,871 | $563,733 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 22 services
| Injection, pembrolizumab, 1 mg | 13 | $940,749 | None |
| Injection, denosumab, 1 mg | 17 | $175,535 | None |
| Administration of chemotherapy into vein, 1 hour or less | 48 | $53,816 | $137 |
| Long return visit (40+ min) | 120 | $45,889 | $166 |
| Return visit (30+ min) | 151 | $34,716 | $113 |
| New patient visit (60+ min) | 51 | $10,210 | $200 |
| Administration of additional new drug or substance into vein, 1 hour or less | 21 | $5,966 | $67 |
| Injection of additional new drug or substance into vein | 32 | $5,595 | $15 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 83 | $4,946 | $29 |
| Short return visit (20+ min) | 51 | $4,501 | $73 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $2,883 | $107 |
| Collection of blood sample from implanted device | 24 | $2,668 | $29 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,490 | $156 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 22 | $2,415 | $71 |
| Injection of drug or substance under skin or into muscle | 33 | $2,272 | $13 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $1,534 | $32 |
| Infusion, normal saline solution , 1000 cc | 57 | $1,260 | None |
| Injection, carboplatin, 50 mg | 17 | $930 | None |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 13 | $572 | $44 |
| 5% dextrose/water (500 ml = 1 unit) | 26 | $131 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 24 | $97 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 15 | $85 | None |
2022: 24 services
| Injection, pembrolizumab, 1 mg | 15 | $691,927 | None |
| Injection, denosumab, 1 mg | 20 | $155,435 | None |
| Administration of chemotherapy into vein, 1 hour or less | 53 | $59,323 | $139 |
| Long return visit (40+ min) | 126 | $45,779 | $162 |
| Return visit (30+ min) | 134 | $33,066 | $109 |
| New patient visit (60+ min) | 49 | $9,736 | $199 |
| Administration of additional new drug or substance into vein, 1 hour or less | 22 | $7,228 | $69 |
| Injection of additional new drug or substance into vein | 27 | $6,145 | $16 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 38 | $4,894 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $4,696 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $4,362 | $174 |
| Short return visit (20+ min) | 49 | $4,116 | $67 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 64 | $3,325 | $29 |
| Telephone medical discussion with physician, 21-30 minutes | 20 | $3,207 | $107 |
| Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise | 11 | $2,685 | $192 |
| Administration of additional new drug or substance into vein using push technique | 13 | $2,426 | $59 |
| Injection of drug or substance under skin or into muscle | 39 | $2,241 | $13 |
| Collection of blood sample from implanted device | 11 | $994 | $28 |
| Infusion, normal saline solution , 1000 cc | 58 | $802 | None |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 18 | $677 | $34 |
| Injection, carboplatin, 50 mg | 11 | $559 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 15 | $82 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 21 | $63 | None |
| 5% dextrose/water (500 ml = 1 unit) | 18 | $43 | None |
2021: 22 services
| Injection, denosumab, 1 mg | 11 | $90,067 | None |
| Administration of chemotherapy into vein, 1 hour or less | 35 | $45,817 | $151 |
| Return visit (30+ min) | 124 | $40,825 | $115 |
| Long return visit (40+ min) | 82 | $34,386 | $166 |
| New patient visit (60+ min) | 47 | $9,494 | $202 |
| Telephone medical discussion with physician, 21-30 minutes | 24 | $6,523 | $119 |
| Short return visit (20+ min) | 52 | $5,930 | $77 |
| Administration of additional new drug or substance into vein, 1 hour or less | 14 | $4,496 | $70 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 35 | $4,237 | $65 |
| Injection of additional new drug or substance into vein | 23 | $3,550 | $17 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 54 | $3,133 | $30 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $3,088 | $182 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $2,343 | $94 |
| Collection of blood sample from implanted device | 14 | $1,868 | $28 |
| Injection of drug or substance under skin or into muscle | 21 | $1,566 | $14 |
| Telephone medical discussion with physician, 11-20 minutes | 12 | $1,058 | $71 |
| Injection, carboplatin, 50 mg | 12 | $815 | None |
| Infusion, normal saline solution , 1000 cc | 41 | $804 | None |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 16 | $730 | $35 |
| 5% dextrose/water (500 ml = 1 unit) | 17 | $91 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 19 | $79 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 11 | $38 | None |
2020: 27 services
| Injection, denosumab, 1 mg | 12 | $55,036 | None |
| Administration of chemotherapy into vein, 1 hour or less | 38 | $38,044 | $145 |
| Return visit (30+ min) | 114 | $27,603 | $97 |
| Long return visit (40+ min) | 55 | $12,944 | $136 |
| Short return visit (20+ min) | 86 | $7,775 | $62 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 11 | $6,525 | $73 |
| Injection of additional new drug or substance into vein | 27 | $6,456 | $17 |
| New patient visit (60+ min) | 31 | $5,996 | $193 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 38 | $4,651 | $66 |
| Administration of additional new drug or substance into vein, 1 hour or less | 18 | $4,586 | $71 |
| Telephone medical discussion with physician, 21-30 minutes | 28 | $3,630 | $101 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,292 | $183 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $2,180 | $95 |
| Telephone medical discussion with physician, 11-20 minutes | 26 | $2,138 | $71 |
| New patient visit (45+ min) | 15 | $2,121 | $141 |
| Extended patient service without direct patient contact, first hour | 18 | $2,044 | $102 |
| Collection of blood sample from implanted device | 12 | $1,292 | $26 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 15 | $1,215 | $30 |
| Administration of chemotherapy into vein, each additional hour | 14 | $1,190 | $31 |
| Injection of drug or substance under skin or into muscle | 30 | $949 | $13 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 16 | $808 | $35 |
| Infusion, normal saline solution , 1000 cc | 40 | $696 | None |
| Injection, carboplatin, 50 mg | 11 | $601 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 13 | $193 | None |
| 5% dextrose/water (500 ml = 1 unit) | 18 | $132 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 17 | $110 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 24 | $94 | None |
2019: 28 services
| Injection, pegfilgrastim, 6 mg | 11 | $86,865 | None |
| Return visit (30+ min) | 151 | $43,456 | $96 |
| Administration of chemotherapy into vein, 1 hour or less | 63 | $40,631 | $141 |
| Short return visit (20+ min) | 130 | $12,789 | $63 |
| Long return visit (40+ min) | 50 | $7,733 | $125 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 45 | $7,500 | $31 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 11 | $6,285 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 34 | $6,270 | $179 |
| Administration of additional new drug or substance into vein, 1 hour or less | 21 | $6,041 | $69 |
| New patient visit (60+ min) | 28 | $5,286 | $189 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 48 | $5,090 | $64 |
| New patient visit (45+ min) | 30 | $4,383 | $146 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $3,038 | $92 |
| Injection, palonosetron hcl, 25 mcg | 12 | $2,901 | None |
| Administration of chemotherapy into vein, each additional hour | 21 | $2,430 | $30 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 14 | $2,342 | $71 |
| Injection of drug or substance under skin or into muscle | 44 | $1,825 | $16 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 50 | $1,607 | $8 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 25 | $1,144 | $35 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $1,116 | $31 |
| Irrigation of implanted venous access drug delivery device | 19 | $982 | $28 |
| Injection, carboplatin, 50 mg | 13 | $816 | None |
| Insertion of needle into vein for collection of blood sample | 52 | $588 | $3 |
| Injection, ranitidine hydrochloride, 25 mg | 13 | $264 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 40 | $219 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 32 | $164 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 12 | $45 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 16 | $23 | None |
2018: 29 services
| Administration of chemotherapy into vein, 1 hour or less | 75 | $58,584 | $143 |
| Injection, denosumab, 1 mg | 14 | $50,169 | None |
| Return visit (30+ min) | 170 | $46,424 | $95 |
| Short return visit (20+ min) | 160 | $17,614 | $65 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 16 | $13,926 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 62 | $10,120 | $31 |
| Injection, palonosetron hcl, 25 mcg | 21 | $8,770 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 33 | $8,501 | $70 |
| Long return visit (40+ min) | 46 | $8,369 | $129 |
| New patient visit (60+ min) | 33 | $6,237 | $189 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 45 | $5,821 | $65 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $4,501 | $180 |
| New patient visit (45+ min) | 31 | $4,398 | $142 |
| Administration of chemotherapy into vein, each additional hour | 33 | $3,851 | $31 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 66 | $2,388 | $9 |
| Injection of drug or substance under skin or into muscle | 51 | $2,307 | $20 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $2,223 | $93 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 13 | $1,440 | None |
| Injection, zoledronic acid, 1 mg | 11 | $1,239 | None |
| Injection, carboplatin, 50 mg | 20 | $1,078 | None |
| Advance care planning, first 30 minutes | 13 | $1,067 | $76 |
| Irrigation of implanted venous access drug delivery device | 16 | $1,064 | $28 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 23 | $1,004 | $35 |
| Insertion of needle into vein for collection of blood sample | 69 | $770 | $3 |
| Injection, ranitidine hydrochloride, 25 mg | 12 | $506 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 54 | $280 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 48 | $143 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 14 | $50 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 11 | $28 | None |
2017: 29 services
| Injection, pemetrexed, not otherwise specified, 10 mg | 13 | $213,456 | None |
| Injection, pegfilgrastim, 6 mg | 12 | $59,816 | None |
| Administration of chemotherapy into vein, 1 hour or less | 82 | $52,517 | $142 |
| Return visit (30+ min) | 135 | $28,904 | $98 |
| Short return visit (20+ min) | 197 | $27,536 | $64 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 12 | $11,882 | None |
| Long return visit (40+ min) | 54 | $9,822 | $131 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 67 | $7,700 | $31 |
| Administration of additional new drug or substance into vein, 1 hour or less | 39 | $6,652 | $67 |
| Injection, palonosetron hcl, 25 mcg | 18 | $6,546 | None |
| New patient visit (60+ min) | 25 | $4,736 | $189 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 38 | $4,252 | $64 |
| New patient visit (45+ min) | 22 | $3,330 | $151 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $3,246 | $180 |
| Injection of drug or substance under skin or into muscle | 47 | $3,027 | $25 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 69 | $2,487 | $10 |
| Administration of chemotherapy into vein, each additional hour | 27 | $2,243 | $28 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $2,139 | $93 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 14 | $1,784 | $69 |
| Injection, zoledronic acid, 1 mg | 13 | $1,729 | None |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 12 | $1,712 | None |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 32 | $1,599 | $35 |
| Injection, carboplatin, 50 mg | 23 | $1,461 | None |
| Advance care planning, first 30 minutes | 16 | $1,247 | $73 |
| Irrigation of implanted venous access drug delivery device | 13 | $754 | $24 |
| Insertion of needle into vein for collection of blood sample | 71 | $723 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 59 | $262 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 48 | $131 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 18 | $114 | None |
2016: 33 services
| Injection, nivolumab, 1 mg | 13 | $165,347 | None |
| Administration of chemotherapy into vein, 1 hour or less | 97 | $59,801 | $141 |
| Injection, pegfilgrastim, 6 mg | 11 | $49,876 | None |
| Short return visit (20+ min) | 235 | $33,230 | $64 |
| Return visit (30+ min) | 120 | $29,577 | $97 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 19 | $17,601 | None |
| Injection, palonosetron hcl, 25 mcg | 26 | $10,047 | None |
| Long return visit (40+ min) | 59 | $9,887 | $134 |
| Injection, docetaxel, 1 mg | 15 | $8,318 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 34 | $8,253 | $65 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 75 | $8,161 | $31 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 42 | $4,697 | $64 |
| Administration of chemotherapy into vein, each additional hour | 36 | $3,704 | $29 |
| New patient visit (60+ min) | 18 | $3,397 | $189 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 88 | $3,104 | $10 |
| Injection of drug or substance under skin or into muscle | 54 | $3,082 | $25 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 20 | $3,048 | $69 |
| New patient visit (45+ min) | 20 | $2,926 | $146 |
| Injection, zoledronic acid, 1 mg | 17 | $2,904 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $2,886 | $180 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 17 | $2,227 | None |
| Injection, carboplatin, 50 mg | 24 | $1,961 | None |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $1,945 | $122 |
| New patient visit (30+ min) | 20 | $1,926 | $96 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 26 | $1,570 | $35 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $1,390 | $93 |
| Irrigation of implanted venous access drug delivery device | 21 | $949 | $24 |
| Insertion of needle into vein for collection of blood sample | 92 | $926 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 65 | $326 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 56 | $149 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 14 | $119 | None |
| Injection, ranitidine hydrochloride, 25 mg | 17 | $68 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 19 | $20 | None |
2015: 32 services
| Administration of chemotherapy into vein, 1 hour or less | 75 | $48,199 | $140 |
| Return visit (30+ min) | 174 | $31,863 | $93 |
| Short return visit (20+ min) | 213 | $30,015 | $64 |
| Injection, palonosetron hcl, 25 mcg | 32 | $13,082 | None |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 15 | $10,797 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 66 | $8,480 | $31 |
| Injection, docetaxel, 1 mg | 12 | $6,673 | None |
| Long return visit (40+ min) | 40 | $6,044 | $129 |
| Administration of additional new drug or substance into vein, 1 hour or less | 30 | $5,812 | $65 |
| Injection, zoledronic acid, 1 mg | 24 | $5,720 | None |
| New patient visit (45+ min) | 25 | $3,824 | $153 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 34 | $3,694 | $65 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 26 | $3,604 | $71 |
| New patient visit (60+ min) | 17 | $3,195 | $188 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 13 | $3,048 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $2,899 | $181 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 73 | $2,862 | $10 |
| Administration of chemotherapy into vein, each additional hour | 33 | $2,719 | $29 |
| Injection of drug or substance under skin or into muscle | 47 | $2,571 | $26 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $2,421 | $93 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 31 | $1,707 | $35 |
| New patient visit (30+ min) | 17 | $1,582 | $93 |
| Injection, carboplatin, 50 mg | 20 | $1,346 | None |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $1,263 | $31 |
| Irrigation of implanted venous access drug delivery device | 18 | $1,029 | $26 |
| Insertion of needle into vein for collection of blood sample | 72 | $817 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 59 | $345 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 40 | $94 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 16 | $73 | None |
| Injection, ranitidine hydrochloride, 25 mg | 11 | $46 | None |
| Injection, magnesium sulfate, per 500 mg | 13 | $33 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 13 | $16 | None |
2014: 29 services
| Administration of chemotherapy into vein, 1 hour or less | 74 | $44,306 | $138 |
| Short return visit (20+ min) | 200 | $27,543 | $65 |
| Return visit (30+ min) | 111 | $24,565 | $98 |
| Injection, palonosetron hcl, 25 mcg | 32 | $13,049 | None |
| Injection, zoledronic acid, 1 mg | 20 | $10,546 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 37 | $9,121 | $64 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 62 | $8,413 | $30 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 51 | $4,936 | $64 |
| Long return visit (40+ min) | 32 | $4,842 | $131 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 23 | $4,415 | None |
| Administration of chemotherapy into vein, each additional hour | 36 | $4,099 | $28 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 73 | $3,307 | $10 |
| New patient visit (45+ min) | 20 | $3,050 | $152 |
| New patient visit (60+ min) | 16 | $3,027 | $189 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 41 | $2,708 | $35 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 22 | $2,486 | $67 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $2,220 | $93 |
| Injection of drug or substance under skin or into muscle | 36 | $1,964 | $25 |
| Irrigation of implanted venous access drug delivery device | 23 | $1,562 | $26 |
| Injection, carboplatin, 50 mg | 20 | $1,484 | None |
| Insertion of needle into vein for collection of blood sample | 75 | $941 | $3 |
| Injection, paclitaxel, 30 mg | 13 | $877 | None |
| Short return visit | 12 | $544 | $42 |
| Injection, dexamethasone sodium phosphate, 1 mg | 67 | $400 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 41 | $143 | None |
| Injection, ranitidine hydrochloride, 25 mg | 14 | $67 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 11 | $36 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 18 | $17 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 16 | $12 | None |
2013: 29 services
| Administration of chemotherapy into vein, 1 hour or less | 70 | $37,894 | $149 |
| Short return visit (20+ min) | 178 | $26,320 | $64 |
| Return visit (30+ min) | 125 | $25,343 | $97 |
| Injection, palonosetron hcl, 25 mcg | 36 | $14,825 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 33 | $7,877 | $74 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 46 | $4,873 | $62 |
| Administration of chemotherapy into vein, each additional hour | 34 | $4,149 | $31 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 39 | $4,117 | $32 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 19 | $3,674 | $78 |
| New patient visit (45+ min) | 24 | $3,537 | $147 |
| Long return visit (40+ min) | 20 | $2,555 | $128 |
| New patient visit (60+ min) | 13 | $2,431 | $187 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $2,339 | $90 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 71 | $2,326 | $11 |
| Administration of additional new drug or substance into vein using push technique | 15 | $2,317 | $64 |
| Injection of drug or substance under skin or into muscle | 27 | $2,265 | $25 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 39 | $2,229 | $34 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 11 | $1,954 | None |
| Injection, carboplatin, 50 mg | 23 | $1,484 | None |
| New patient visit (30+ min) | 13 | $1,318 | $101 |
| Irrigation of implanted venous access drug delivery device | 14 | $1,236 | $25 |
| Injection, paclitaxel, 30 mg | 12 | $1,012 | None |
| Insertion of needle into vein for collection of blood sample | 77 | $721 | $3 |
| Short return visit | 11 | $549 | $42 |
| Injection, dexamethasone sodium phosphate, 1 mg | 61 | $260 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 35 | $103 | None |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 41 | $48 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 15 | $26 | None |
| Injection, magnesium sulfate, per 500 mg | 12 | $25 | None |
Drugs they prescribed that Part D paid
$1,994,600
Pharmacies billed $1,994,600 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (13 of 649) in 2024. At or below the middle of the specialty; the typical medical oncology clinician is at 6%.
503 generic and 146 brand-name prescriptions · $1,994,600 in drug cost · 45 antibiotic prescriptions to 19 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Tagrisso | 42 | $884,479 | $21,059 |
| Ibrance | 14 | $226,211 | $16,158 |
| Eliquis | 30 | $35,836 | $1,195 |
| Tenofovir Disoproxil | 16 | $4,244 | $265 |
| Anastrozole | 96 | $3,166 | $33 |
See all 17 drugs
| Tagrisso | 42 | $884,479 | $21,059 |
| Ibrance | 14 | $226,211 | $16,158 |
| Eliquis | 30 | $35,836 | $1,195 |
| Tenofovir Disoproxil | 16 | $4,244 | $265 |
| Anastrozole | 96 | $3,166 | $33 |
| Dexamethasone | 35 | $968 | $28 |
| Ondansetron | 59 | $915 | $16 |
| Tamoxifen Citrate | 25 | $861 | $34 |
| Prochlorperazine Maleate | 41 | $480 | $12 |
| Acyclovir | 34 | $342 | $10 |
| Sulfamethoxazole-Trimethoprim | 33 | $280 | $8 |
| Levothyroxine | 15 | $250 | $17 |
| Hydroxyurea | 12 | $167 | $14 |
| Prednisone | 17 | $141 | $8 |
| Pantoprazole | 11 | $136 | $12 |
| Potassium Chloride | 14 | $111 | $8 |
| Allopurinol | 13 | $12 | $1 |
Year by year
| 2024 | 649 | 143 | 2% (13) | 22% | $1,994,600 |
| 2023 | 660 | 128 | 2% (11) | 20% | $1,585,053 |
| 2022 | 469 | 110 | 3% (13) | None | $888,157 |
| 2021 | 586 | 115 | 3% (18) | 16% | $698,418 |
| 2020 | 687 | 115 | 5% (33) | 29% | $1,347,799 |
| 2019 | 708 | 123 | 6% (44) | 27% | $1,285,592 |
| 2018 | 746 | 140 | 5% (35) | 19% | $1,024,196 |
| 2017 | 779 | 130 | 5% (39) | 14% | $894,906 |
| 2016 | 790 | 142 | 5% (38) | 11% | $587,148 |
| 2015 | 783 | 129 | 9% (70) | 15% | $696,550 |
| 2014 | 584 | 108 | 8% (45) | 15% | $475,564 |
| 2013 | 557 | 103 | 7% (40) | 20% | $317,128 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 15 drugs
| Tagrisso | 19 | $461,670 | $24,298 |
| Ibrance | 21 | $351,879 | $16,756 |
| Eliquis | 19 | $21,615 | $1,138 |
| Anastrozole | 89 | $4,175 | $47 |
| Tamoxifen Citrate | 38 | $1,418 | $37 |
| Hydroxyurea | 30 | $1,191 | $40 |
| Ondansetron | 34 | $853 | $25 |
| Acyclovir | 39 | $782 | $20 |
| Dexamethasone | 24 | $601 | $25 |
| Pantoprazole | 44 | $493 | $11 |
| Prochlorperazine Maleate | 31 | $461 | $15 |
| Levothyroxine | 25 | $360 | $14 |
| Sulfamethoxazole-Trimethoprim | 40 | $359 | $9 |
| Prednisone | 18 | $147 | $8 |
| Alendronate | 12 | $78 | $7 |
2022: 13 drugs
| Tagrisso | 12 | $272,621 | $22,718 |
| Ibrance | 13 | $191,848 | $14,758 |
| Eliquis | 12 | $13,907 | $1,159 |
| Anastrozole | 54 | $1,367 | $25 |
| Hydroxyurea | 23 | $862 | $37 |
| Prochlorperazine Maleate | 45 | $861 | $19 |
| Ondansetron | 44 | $789 | $18 |
| Tamoxifen Citrate | 22 | $724 | $33 |
| Dexamethasone | 30 | $615 | $20 |
| Exemestane | 12 | $517 | $43 |
| Prednisone | 36 | $363 | $10 |
| Levothyroxine | 13 | $295 | $23 |
| Pantoprazole | 13 | $130 | $10 |
2021: 16 drugs
| Tagrisso | 15 | $283,264 | $18,884 |
| Ibrance | 12 | $172,345 | $14,362 |
| Eliquis | 29 | $25,712 | $887 |
| Octreotide Acetate | 12 | $14,704 | $1,225 |
| Abiraterone Acetate | 12 | $6,316 | $526 |
| Exemestane | 24 | $4,725 | $197 |
| Anastrozole | 95 | $3,673 | $39 |
| Hydroxyurea | 25 | $1,031 | $41 |
| Dexamethasone | 30 | $792 | $26 |
| Ondansetron | 34 | $675 | $20 |
| Levothyroxine | 20 | $461 | $23 |
| Prochlorperazine Maleate | 33 | $404 | $12 |
| Pantoprazole | 19 | $363 | $19 |
| Prednisone | 40 | $352 | $9 |
| Hydrocodone-Acetaminophen | 12 | $214 | $18 |
| Sulfamethoxazole-Trimethoprim | 14 | $76 | $5 |
2020: 18 drugs
| Revlimid | 36 | $436,475 | $12,124 |
| Tagrisso | 17 | $250,867 | $14,757 |
| Venclexta | 11 | $66,743 | $6,068 |
| Eliquis | 59 | $27,766 | $471 |
| Exemestane | 36 | $8,911 | $248 |
| Anastrozole | 112 | $4,778 | $43 |
| Colchicine | 12 | $3,146 | $262 |
| Tamoxifen Citrate | 19 | $1,499 | $79 |
| Hydroxyurea | 23 | $1,001 | $44 |
| Dexamethasone | 29 | $733 | $25 |
| Ondansetron | 31 | $503 | $16 |
| Prochlorperazine Maleate | 32 | $432 | $13 |
| Potassium Chloride | 16 | $277 | $17 |
| Prednisone | 24 | $248 | $10 |
| Pantoprazole | 12 | $234 | $19 |
| Hydrocodone-Acetaminophen | 13 | $144 | $11 |
| Acyclovir | 12 | $80 | $7 |
| Lorazepam | 14 | $73 | $5 |
2019: 19 drugs
| Revlimid | 35 | $475,526 | $13,586 |
| Caprelsa | 13 | $213,940 | $16,457 |
| Ibrance | 11 | $130,349 | $11,850 |
| Imatinib Mesylate | 12 | $40,570 | $3,381 |
| Eliquis | 52 | $23,804 | $458 |
| Exemestane | 23 | $9,966 | $433 |
| Anastrozole | 172 | $4,832 | $28 |
| Colchicine | 11 | $3,847 | $350 |
| Dexamethasone | 38 | $730 | $19 |
| Tamoxifen Citrate | 18 | $727 | $40 |
| Hydroxyurea | 13 | $692 | $53 |
| Prochlorperazine Maleate | 14 | $416 | $30 |
| Levothyroxine | 22 | $352 | $16 |
| Hydrocodone-Acetaminophen | 14 | $283 | $20 |
| Prednisone | 20 | $172 | $9 |
| Venlafaxine Hcl Er | 12 | $161 | $13 |
| Ondansetron | 14 | $147 | $10 |
| Alendronate | 11 | $92 | $8 |
| Sulfamethoxazole-Trimethoprim | 16 | $33 | $2 |
2018: 21 drugs
| Ibrance | 21 | $237,952 | $11,331 |
| Caprelsa | 11 | $159,237 | $14,476 |
| Imatinib Mesylate | 24 | $153,209 | $6,384 |
| Revlimid | 11 | $124,904 | $11,355 |
| Tarceva | 14 | $108,729 | $7,766 |
| Votrient | 11 | $74,099 | $6,736 |
| Exemestane | 27 | $15,000 | $556 |
| Eliquis | 28 | $12,202 | $436 |
| Anastrozole | 208 | $4,930 | $24 |
| Tamoxifen Citrate | 38 | $1,915 | $50 |
| Hydroxyurea | 16 | $787 | $49 |
| Dexamethasone | 29 | $483 | $17 |
| Ondansetron | 22 | $387 | $18 |
| Prochlorperazine Maleate | 33 | $353 | $11 |
| Alendronate | 18 | $268 | $15 |
| Prednisone | 26 | $258 | $10 |
| Duloxetine | 13 | $218 | $17 |
| Levothyroxine | 17 | $188 | $11 |
| Venlafaxine Hcl Er | 14 | $157 | $11 |
| Gabapentin | 11 | $103 | $9 |
| Lorazepam | 17 | $62 | $4 |
2017: 22 drugs
| Imatinib Mesylate | 25 | $166,449 | $6,658 |
| Caprelsa | 11 | $152,932 | $13,903 |
| Ibrance | 13 | $141,959 | $10,920 |
| Tarceva | 18 | $132,851 | $7,381 |
| Exemestane | 26 | $11,881 | $457 |
| Anastrozole | 250 | $4,809 | $19 |
| Tamoxifen Citrate | 17 | $986 | $58 |
| Hydroxyurea | 19 | $848 | $45 |
| Potassium Chloride | 30 | $481 | $16 |
| Morphine Sulfate Er | 15 | $378 | $25 |
| Dexamethasone | 27 | $341 | $13 |
| Ondansetron Odt | 16 | $290 | $18 |
| Prochlorperazine Maleate | 34 | $228 | $7 |
| Hydrocodone-Acetaminophen | 12 | $175 | $15 |
| Ondansetron | 17 | $169 | $10 |
| Duloxetine | 11 | $165 | $15 |
| Prednisone | 21 | $162 | $8 |
| Venlafaxine Hcl Er | 14 | $160 | $11 |
| Alendronate | 22 | $150 | $7 |
| Gabapentin | 11 | $128 | $12 |
| Lorazepam | 14 | $42 | $3 |
| Furosemide | 11 | $29 | $3 |
2016: 18 drugs
| Caprelsa | 12 | $154,304 | $12,859 |
| Imatinib Mesylate | 19 | $120,976 | $6,367 |
| Tarceva | 19 | $112,796 | $5,937 |
| Imbruvica | 12 | $40,273 | $3,356 |
| Exemestane | 30 | $11,340 | $378 |
| Anastrozole | 255 | $4,078 | $16 |
| Tamoxifen Citrate | 32 | $1,138 | $36 |
| Oxycodone-Acetaminophen | 15 | $533 | $36 |
| Hydroxyurea | 35 | $523 | $15 |
| Gabapentin | 36 | $406 | $11 |
| Dexamethasone | 32 | $373 | $12 |
| Ondansetron Odt | 14 | $287 | $20 |
| Potassium Chloride | 12 | $187 | $16 |
| Prochlorperazine Maleate | 23 | $172 | $7 |
| Alendronate | 18 | $171 | $10 |
| Prednisone | 21 | $138 | $7 |
| Zolpidem | 12 | $120 | $10 |
| Lorazepam | 31 | $120 | $4 |
2015: 19 drugs
| Tarceva | 27 | $194,626 | $7,208 |
| Gleevec | 23 | $186,567 | $8,112 |
| Imbruvica | 14 | $43,606 | $3,115 |
| Exemestane | 26 | $11,524 | $443 |
| Enoxaparin | 14 | $7,584 | $542 |
| Anastrozole | 194 | $3,087 | $16 |
| Tamoxifen Citrate | 48 | $1,329 | $28 |
| Oxycodone-Acetaminophen | 24 | $779 | $32 |
| Hydrocodone-Acetaminophen | 21 | $534 | $25 |
| Hydroxyurea | 31 | $452 | $15 |
| Potassium Chloride | 17 | $302 | $18 |
| Pantoprazole | 25 | $240 | $10 |
| Gabapentin | 18 | $226 | $13 |
| Dexamethasone | 15 | $213 | $14 |
| Lorazepam | 39 | $179 | $5 |
| Alendronate | 18 | $167 | $9 |
| Sulfamethoxazole-Trimethoprim | 21 | $132 | $6 |
| Prochlorperazine Maleate | 13 | $93 | $7 |
| Zolpidem | 11 | $67 | $6 |
2014: 10 drugs
| Caprelsa | 12 | $137,381 | $11,448 |
| Tarceva | 18 | $124,877 | $6,938 |
| Enoxaparin | 12 | $7,724 | $644 |
| Anastrozole | 196 | $3,739 | $19 |
| Tamoxifen Citrate | 61 | $1,655 | $27 |
| Hydrocodone-Acetaminophen | 19 | $455 | $24 |
| Letrozole | 13 | $331 | $25 |
| Potassium Chloride | 15 | $327 | $22 |
| Gabapentin | 11 | $179 | $16 |
| Prednisone | 17 | $80 | $5 |
2013: 11 drugs
| Tarceva | 11 | $50,365 | $4,579 |
| Anastrozole | 208 | $6,183 | $30 |
| Exemestane | 12 | $3,593 | $299 |
| Tamoxifen Citrate | 35 | $930 | $27 |
| Potassium Chloride | 17 | $456 | $27 |
| Pantoprazole | 19 | $338 | $18 |
| Letrozole | 15 | $263 | $18 |
| Hydrocodone-Acetaminophen | 14 | $212 | $15 |
| Oxycodone-Acetaminophen | 12 | $137 | $11 |
| Prednisone | 14 | $47 | $3 |
| Furosemide | 11 | $38 | $3 |
Money from drug and device companies
$38 in 2024
| 2024 | 1 | 2 | None | $38 |
| 2023 | 2 | 3 | None | $163 |
| 2021 | 2 | 4 | None | $275 |
| 2020 | 2 | 4 | None | $54 |
| 2019 | 3 | 3 | None | $53 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Lynparza | $38 | 2 payments
|
See all 2 published payments
| AstraZeneca Pharmaceuticals LP | Meals · 2024-09-16 | Lynparza | $20 |
| AstraZeneca Pharmaceuticals LP | Meals · 2024-08-15 | Lynparza | $18 |
See earlier years (2023, 2021, 2020, 2019)
2023: $163
| AstraZeneca Pharmaceuticals LP | Enhertu | $119 | 1 payment
|
| Pfizer | Ibrance | $44 | 2 payments
|
2021: $275
| AstraZeneca Pharmaceuticals LP | None | $246 | 2 payments
|
| Pfizer | Lorbrena | $29 | 2 payments
|
2020: $54
| Pfizer | Xalkori | $38 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | None | $16 | 1 payment
|
2019: $53
| Merck Sharp & Dohme | Keytruda | $20 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $18 | 1 payment
|
| Janssen Biotech | Imbruvica | $15 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1013074632
- Licence
- CA G60386California G60386: Current · expires 2027-01-31
- Trained
- University of California, San Francisco School of Medicine, 1984
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 218 De Anza Blvd, San Mateo, CA, 94402
- NPI first listed
- 2007-01-02
- NPI last updated
- 2007-07-08
This is when the NPI record was last certified, not a medical board exam.